New antibody aims to shield hearts after stent surgery
NCT ID NCT06678074
First seen Apr 05, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This early-stage study tests a drug called atibuclimab (IC14) in 10 adults who had a severe heart attack (STEMI) and received a stent. The drug is given through a vein to try to prevent more heart muscle damage. Researchers will check safety and measure heart function and inflammation, comparing results to a placebo group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22908-1394, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.